SynthesisEuropean journal of medical research2025
Efficacy of cyclin-dependent kinases 4 and 6 inhibitors in the treatment of HR +/HER2 - advanced breast cancer: a meta-analysis.
Synthesis in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimThis study investigates the efficacy and safety of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) in treating hormone receptor-positive (HR +), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.
methodsA systematic review of randomized clinical trials (RCTs) from 2015 to 2024 was conducted using databases such as PubMed, Google Scholar, Embase, and Cochrane. Data were collected on treatment outcomes, including complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), overall response rate (ORR), and treatment-related adverse events (TRAEs). Analysis was performed using Review Manager 5.4.1, following PRISMA guidelines, with registration in the PROSPERO database (ID: CRD42023471168).
results1223 studies screened, 13 met inclusion criteria. CDK4/6i + ET significantly reduced PD rates and increased SD compared to ET + chemotherapy. No significant differences were observed in CR, PR, or SD between the groups. CDK4/6i + ET demonstrated a favorable safety profile with fewer high-grade TRAEs but had a higher incidence of grade 3-4 adverse events than ET alone.
conclusionCDK4/6i combined with ET improves disease control by decreasing progression and increasing stability, though it shows a lower PR rate than ET + chemotherapy in HR + /HER2 - advanced breast cancer. These findings underscore the need to balance efficacy with tolerability when selecting treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.